Residual disease in lymph nodes has no influence on survival in patients with incidental gallbladder cancer – institution experience with literature review
Abstract
Background.
A better appreciation of the course and factors that influence incidental gallbladder cancer (iGBC) is needed to develop treatment strategies aimed to improve outcomes. The purpose of this study was to determine the influence of residual disease in the liver and lymph nodes on overall survival in re-resected patients with iGBC.
Patients and methods.
Patients undergoing radical re-resection for iGBC from January 2012 to December 2018 were retrospectively identified. Patients with a 5-year follow-up and submitted to complete resection with stage I, II and III disease were analysed. The influence of residual disease (RD) in liver and lymph nodes on survival was assessed using the Kaplan – Meier curves. In addition the rest of the group was assessed based on type of primary/secondary procedure, number of harvested lymph nodes and RD in liver and/or lymph nodes.
Results.
In this retrospective study 48 out of 58 patients underwent re-resection. Among the group with a 5-year follow-up (re-operation between 2012-2014), 22 patients out of 28 were re-resected. Survival analysis showed that patients with no RD in the liver and lymph nodes had statistically significant better 5-year survival than those with RD. Comparing 5-year survival rate in patients with RD in the liver or lymph nodes against no RD group, patients with RD in the liver had statistically significantly worse 5-year survival, while lymph node metastases did not show any statistically significant different 5-year survival. Besides, a statistically significant better prognosis was found in stage II disease compared to stage III.
Conclusions.
The most important predictor of a 5-year survival in our study is RD in liver and stage of the disease. Lymph node metastases did not have any impact on the overall 5-year survival rate.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Radiology and Oncology

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
License to Publish
Please read the terms of this agreement, print, initial page 1, sign page 3, scan and send the document as one file attached to an e-mail to gsersa@onko-i.si